Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Case of seasonal reassortant A(H1N2) influenza virus infection, the Netherlands, March 2018.

Meijer A, Swaan CM, Voerknecht M, Jusic E, van den Brink S, Wijsman LA, Voordouw BC, Donker GA, Sleven J, Dorigo-Zetsma WW, Svraka S, van Boven M, Haverkate MR, Timen A, van Dissel JT, Koopmans MP, Bestebroer TM, Fouchier RA.

Euro Surveill. 2018 Apr;23(15). doi: 10.2807/1560-7917.ES.2018.23.15.18-00160.

2.

Quantifying within-household transmission of extended-spectrum β-lactamase-producing bacteria.

Haverkate MR, Platteel TN, Fluit AC, Cohen Stuart JW, Leverstein-van Hall MA, Thijsen SFT, Scharringa J, Kloosterman RC, Bonten MJM, Bootsma MCJ.

Clin Microbiol Infect. 2017 Jan;23(1):46.e1-46.e7. doi: 10.1016/j.cmi.2016.08.021. Epub 2016 Sep 3.

3.

Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study.

Arcilla MS, van Hattem JM, Haverkate MR, Bootsma MCJ, van Genderen PJJ, Goorhuis A, Grobusch MP, Lashof AMO, Molhoek N, Schultsz C, Stobberingh EE, Verbrugh HA, de Jong MD, Melles DC, Penders J.

Lancet Infect Dis. 2017 Jan;17(1):78-85. doi: 10.1016/S1473-3099(16)30319-X. Epub 2016 Oct 14.

PMID:
27751772
4.

Electronic and vibronic properties of a discotic liquid-crystal and its charge transfer complex.

Haverkate LA, Zbiri M, Johnson MR, Carter E, Kotlewski A, Picken S, Mulder FM, Kearley GJ.

J Chem Phys. 2014 Jan 7;140(1):014903. doi: 10.1063/1.4856815.

PMID:
24410238
5.

Dynamic solubility limits in nanosized olivine LiFePO4.

Wagemaker M, Singh DP, Borghols WJ, Lafont U, Haverkate L, Peterson VK, Mulder FM.

J Am Chem Soc. 2011 Jul 6;133(26):10222-8. doi: 10.1021/ja2026213. Epub 2011 Jun 9.

PMID:
21598941
6.

Strategies for implementing health promotion programs in multiple American Indian communities.

Edgerly CC, Laing SS, Day AV, Blackinton PM, Pingatore NL, Haverkate RT, Heany JF.

Health Promot Pract. 2009 Apr;10(2 Suppl):109S-117S. doi: 10.1177/1524839908331270.

PMID:
19454757
7.

Discovery of thrombin activatable fibrinolysis inhibitor (TAFI).

Bertina RM, van Tilburg NH, Haverkate F, Bouma BN, von dem Borne PA, Meijers JC, Campbell W, Eaton D, Hendriks DF, Willemse JL.

J Thromb Haemost. 2006 Jan;4(1):256-7. No abstract available.

8.

Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study.

Bots ML, Breteler MM, van Kooten F, Haverkate F, Meijer P, Koudstaal PJ, Grobbee DE, Kluft C.

Haemostasis. 1998 May-Aug;28(3-4):216-22.

PMID:
10420069
9.

Response to activated protein C in subjects with and without dementia. The Dutch Vascular Factors in Dementia Study.

Bots ML, van Kooten F, Breteler MM, Slagboom PE, Hofman A, Haverkate F, Meijer P, Koudstaal PJ, Grobbee DE, Kluft C.

Haemostasis. 1998 May-Aug;28(3-4):209-15.

PMID:
10420068
10.

The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.

Grailhe P, Boyer-Neumann C, Haverkate F, Grimbergen J, Larrieu MJ, Anglés-Cano E.

Blood Coagul Fibrinolysis. 1993 Oct;4(5):679-87.

PMID:
8292717
11.

Factors influencing the structure of terminal plasmin degradation products of human fibrinogen and fibrin.

Nieuwenhuizen W, Vermond A, Haverkate F.

Biochim Biophys Acta. 1981 Feb 27;667(2):321-7.

PMID:
6452172

Supplemental Content

Loading ...
Support Center